AKERO THERAPEUTICS IN

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

30 сен 2024 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

09 сен 2024 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

28 авг 2024 13:05:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

09 авг 2024 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

11 июн 2024 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

08 июн 2024 05:15:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

29 май 2024 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

10 май 2024 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

08 май 2024 04:00:01 Источник Nasdaq GlobeNewswire

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

30 апр 2024 05:00:01 Источник Nasdaq GlobeNewswire

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

08 мар 2024 13:02:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

07 мар 2024 13:01:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

05 мар 2024 18:13:56 Источник Nasdaq GlobeNewswire

Akero Therapeutics Announces Proposed Public Offering of Common Stock

04 мар 2024 13:21:12 Источник Nasdaq GlobeNewswire

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

04 мар 2024 03:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

29 фев 2024 05:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

29 фев 2024 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 05:15:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program

18 дек 2023 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

13 ноя 2023 04:00:00 Источник Nasdaq GlobeNewswire